Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.

The approval makes Ozempic the first once-weekly treatment for type 2 diabetes that not only improves glycemic control but also lowers the risk of eGFR decline, end-stage kidney disease, and cardiovascular death.

Results from the FLOW trial support the decision.

Also Read: Novo Nordisk’s Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says ...